In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Nerlynx (Puma)
- INDICATIONS: Early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy
- CLASS: Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 7–17 hours
- FDA APPROVAL DATE: 07/17/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Boceprevir, Bosentan, Carbamazepine, Cimetidine, Ciprofloxacin, Clarithromycin, Clotrimazole, Cobicistat, Conivaptan, Crizotinib, Cyclosporine, Dabigatran, Digoxin, Diltiazem, Dronedarone, Efavirenz, Enzalutamide, Erythromycin, Etravirine, Fexofenadine, Fluconazole, Fluvoxamine, Grapefruit Juice, H2-receptor antagonists, Idelalisib, Imatinib, Indinavir, Itraconazole, Ketoconazole, Lansoprazole, Lopinavir, Mitotane, Modafinil, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong or moderate CYP3A4 inhibitors or inducers, Tipranavir, Tofisopam, Troleandomycin, Verapamil, Voriconazole - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Epidermal growth factor receptor (EGFR) inhibitor / antagonist
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
